Key insights
- Truist reiterated a Buy rating on Eli Lilly (LLY) following positive retatrutide trial data. The drug's efficacy is comparable to Mounjaro, setting a high bar. Upcoming data in June will determine if retatrutide can differentiate itself by treating difficult-to-treat patients. Seven analysts have revised earnings upwards, reflecting confidence in LLY's pipeline. Wolfe Research also reiterated an Outperform rating. This news is moderately bullish for LLY and the broader pharmaceutical sector.
Investing.com - Truist Securities reiterated a Buy rating on Eli Lilly stock (NYSE:LLY) with a price target of $1,281.00 following the release of retatrutide trial results. The pharmaceutical giant, with a market capitalization of $822 billion, currently trades below its InvestingPro Fair Value, suggesting potential upside for investors.
The firm noted that the retatrutide results are favorable but appear similar to data from Mounjaro that established a high bar for HbA1c and weight loss effects.
Mounjaro at a 15-mg high dose demonstrated 17% weight loss and 1.7% HbA1c reduction in the 40-week SURPASS trial.
Truist said the next important step will be reviewing detailed TRANSCEND-T2D-1 data at the American Diabetes Association Scientific Sessions in June.
The firm stated that the June data will help determine if retatrutide can induce weight loss and HbA1c lowering effects in difficult-to-treat patients, which could differentiate it from Mounjaro. According to InvestingPro Tips, 7 analysts have revised their earnings upwards for the upcoming period, reflecting growing confidence in Eli Lilly’s pipeline. The company is among the 1,400+ US equities covered by comprehensive Pro Research Reports, offering deeper insights into its competitive positioning.
In other recent news, Eli Lilly announced significant results from its Phase 3 TRANSCEND-T2D-1 trial for the investigational drug retatrutide, aimed at treating type 2 diabetes. The trial demonstrated that retatrutide effectively reduced A1C levels by 1.7% to 2.0% across different doses, compared to 0.8% with placebo, highlighting its potential efficacy. Additionally, Eli Lilly’s Ebglyss treatment for pediatric atopic dermatitis met primary and key secondary endpoints in another Phase 3 trial, with 63% of patients achieving a 75% reduction in disease severity.
Analyst activity around Eli Lilly has been mixed recently. Wolfe Research reiterated an Outperform rating with a $1,325 price target, following the positive diabetes trial results. Conversely, HSBC downgraded Eli Lilly to Reduce from Hold, cutting its price target to $850 due to concerns over the obesity drug market’s size and pricing pressures. UBS also maintained a Buy rating with a $1,250 price target amidst ongoing GLP-1 pricing concerns. These developments provide a varied outlook on Eli Lilly’s market position and potential challenges ahead.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.